[Autologous frozen sperm--an alternative in infertility in the patient with invasively treated testicular tumor?].
Through an optimal treatment of testicular cancer the life expectancy of patients is improved, but more early and late complications were observed after different therapeutic procedures and mainly fertility problems come to the fore. In 70% of the patients (n = 30) an abnormal spermiogram was found prior to treatment. At this time 54% of all patients with testicular cancer (n = 61) were 20 to 30 years old and 43% of these patients wish to have a child. After radical retroperitoneal lymph node dissection in 71% of cases (n = 45) a total or partial loss of ejaculation was found. The cytostatic chemotherapy and radiation treatment are the cause of reversible or irreversible reduction in spermatogenesis and possibly mutagenic alterations. There are several alternatives to treat the infertility problems of cured testicular cancer patients and autologous insemination is favoured by the half of these patients. In our experience with cryopreserved sperm (n = 22) only patients with appropriate sperm quality (greater than 10 Mill. sperms/ml, greater than 30% mobile sperms, greater than 30% thaw motility) are suited to this method. In consideration of these parameters only 25% of testicular cancer patients are suited for long-term sperm preservation. The technical problems of sperm preparation, storage and autologous insemination are described in detail.
Schubert
J
J
Klinik für Urologie, Medizinischen Akademie Carl Gustav Carus, Dresden.
Held
H J
HJ
Kelly
L U
LU
Tolkendorf
E
E
D000328:Adult; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007248:Infertility, Male / Q000628:therapy*; D007315:Insemination, Artificial; D007317:Insemination, Artificial, Homologous; D008297:Male; D009845:Oligospermia / Q000628:therapy; D012662:Semen Preservation / Q000379:methods*; D013736:Testicular Neoplasms / Q000150:complications* / Q000628:therapy
Autologes Kryosperma--eine Alternative bei Infertilität des invasiv behandelten Hodentumorpatienten?